BioLife Solutions Inc (BLFS) reports significant improvements in gross margin and EBITDA, despite a drop in total revenue due ...

The company faces competition from home-brew formulations in the media market and established products like cryobags in the CryoCase market. R&D expenses are expected to increase in 2025 ...

and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer ...

On the CryoCase side, that's clearly a direct competitor to cryobags, and they are very well-established and no doubt the most used final dose container. And in that regard, it comes down to the ...

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q4 2024 shareholder and analyst conference call. (Operator Instructions). As a reminder, today's ...

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q4 2024 shareholder and analyst conference call. (Operator Instructions). As a reminder, today's ...

After hours: March 6 at 4:19:23 p.m. EST Loading Chart for BLFS ...